Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.40 +0.77 (+1.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
59 60 Next >
A New BioTech Research Race Is Focused On Improving Life For MS Patients
When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is... 
Via Benzinga
ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
From Alexion
Via Business Wire
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all... 
Via MarketBeat
Intel's Self-Driving Tech Firm Raises Over $800M In IPO, Alphabet Misses Q3 Earnings Expectations, Lyft Cuts Price For Monthly Subscription Plan: Top Stories Wednesday, Oct. 26
Benzinga 
Via Benzinga
AstraZeneca's Imfinzi Combo Scores FDA Approval For Liver Cancer
Via Benzinga
This Growth Stock Rose Last Week. Is It Still a Buy?
Illumina is the dominant player in gene sequencing. 
Via The Motley Fool
AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings
Via Benzinga
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
From AstraZeneca
Via Business Wire
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Twitter Considers Crypto Wallet, Geopolitical Woes To Keep Tesla Shares Volatile, Juul Explores Possible Bailout: Top Stories Tuesday, Oct. 25
Benzinga 
Via Benzinga
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
Via Benzinga
US Stock Futures Down; Big Tech Earnings In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Tuesday after recording gains in the previous session. The Dow Jones jumped by more than 400 points on Monday after all the... 
Via Benzinga
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
From AstraZeneca
Via Business Wire
US Stock Futures Lower Following Friday's Rally; Tesla In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the... 
Via Benzinga
Children's Hospitals Strained After Climbing Cases In Respiratory Illnesses In Kids
Physicians are reporting a sharp increase in cases of the respiratory syncytial virus (RSV), creating capacity issues in several children's hospitals in the U.S. before the typically busier winter... 
Via Benzinga
3 Alzheimer's Therapy Stocks to Invest in
Alzheimer's treatments could make a big winner of these stocks. 
Via The Motley Fool
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
From AstraZeneca
Via Business Wire
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
Beat the Dow Jones With This Unstoppable Dividend Stock
This pharmaceutical stock combines strong financials with an above-average dividend. 
Via The Motley Fool
7 Stocks to Buy When There’s Blood in the Streets
For investors looking for high-quality stocks to buy when there is blood in the streets, there happen to be plenty of companies to pick. 
Via InvestorPlace
2 Top Healthcare Stocks to Buy for the Long Haul
These biotech companies have a long ramp of revenue growth ahead. 
Via The Motley Fool
What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?
AVEO stock jumped on the news that LG Chem will pay $15/share for Aveo Oncology and make it the centerpiece of a new oncology division. 
Via InvestorPlace
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
From Ikena Oncology, Inc.
Via GlobeNewswire
Is This Monster Stock on the Verge of a Home Run?
Ultomiris was just approved in the European Union to treat patients with generalized myasthenia gravis. 
Via The Motley Fool
2 Top Biotech Stocks to Buy Right Now
Healthcare is a reliable sector of the economy for those looking to create wealth over the long haul. 
Via The Motley Fool
3 Incredibly Cheap Blue Chip Stocks to Buy Right Now
It's time to buy the dip in these blue chip stocks. 
Via The Motley Fool
2 No-Brainer Stocks to Buy Right Now for Less Than $100
There's no need to break the bank to buy quality stocks. 
Via The Motley Fool
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.